GBS Inc. (GBS): Price and Financial Metrics


GBS Inc. (GBS): $0.66

0.00 (-0.30%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

GBS POWR Grades


  • GBS scores best on the Sentiment dimension, with a Sentiment rank ahead of 41.71% of US stocks.
  • The strongest trend for GBS is in Stability, which has been heading down over the past 179 days.
  • GBS ranks lowest in Momentum; there it ranks in the 5th percentile.

GBS Stock Summary

  • GBS has a higher market value than only 1.09% of US stocks; more precisely, its current market capitalization is $11,489,307.
  • GBS's went public 1.27 years ago, making it older than merely 1.39% of listed US stocks we're tracking.
  • The ratio of debt to operating expenses for GBS Inc is higher than it is for about merely 0.5% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to GBS Inc are PALT, TSEM, NOVN, MNDO, and ASTI.
  • GBS's SEC filings can be seen here. And to visit GBS Inc's official web site, go to www.gbs.inc.

GBS Valuation Summary

  • In comparison to the median Healthcare stock, GBS's price/earnings ratio is 135.07% lower, now standing at -12.8.
  • Over the past 36 weeks, GBS's price/sales ratio has gone down 344.9.
  • Over the past 36 weeks, GBS's EV/EBIT ratio has gone up 31.3.

Below are key valuation metrics over time for GBS.

Stock Date P/S P/B P/E EV/EBIT
GBS 2021-08-31 212.2 2.5 -12.8 -9.6
GBS 2021-08-30 222.2 2.6 -13.4 -10.3
GBS 2021-08-27 214.8 2.5 -13.0 -9.8
GBS 2021-08-26 209.5 2.5 -12.6 -9.5
GBS 2021-08-25 195.8 2.3 -11.8 -8.5
GBS 2021-08-24 190.5 2.3 -11.5 -8.1

GBS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GBS has a Quality Grade of D, ranking ahead of 11.84% of graded US stocks.
  • GBS's asset turnover comes in at 0.127 -- ranking 152nd of 186 Medical Equipment stocks.
  • 500 - Internal server error

The table below shows GBS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.127 1 -3.273

GBS Stock Price Chart Interactive Chart >

Price chart for GBS

GBS Price/Volume Stats

Current price $0.66 52-week high $5.11
Prev. close $0.66 52-week low $0.38
Day low $0.65 Volume 13,000
Day high $0.71 Avg. volume 1,537,794
50-day MA $0.63 Dividend yield N/A
200-day MA $1.28 Market Cap 9.83M

GBS Inc. (GBS) Company Bio


GBS Inc. operates as a biosensor diagnostic technology company. Its principal product is Saliva Glucose Biosensor, a saliva glucose monitoring system for diabetes management. The company also focuses on developing other diagnostic tests in the areas of biochemistry, tumor markers, immunology, hormones, and other biomarkers. It operates in Mainland China, Hong Kong, Vietnam, and Bangladesh. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was founded in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.


GBS Latest News Stream


Event/Time News Detail
Loading, please wait...

GBS Latest Social Stream


Loading social stream, please wait...

View Full GBS Social Stream

Latest GBS News From Around the Web

Below are the latest news stories about GBS Inc that investors may wish to consider to help them evaluate GBS as an investment opportunity.

GBS: Second Quarter Results

By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT Second Quarter Fiscal Year 2022 Operational and Financial Results GBS, Inc. (NASDAQ:GBS) announced second quarter fiscal year 2022 financial and operational results for the period ending December 31, 2021 in a February 10 th press release and subsequently filed its 10-Q with the SEC. Fiscal Year 2022 Events ➢ $4.7M award from

Yahoo | February 15, 2022

GBS Inc. Reports Second Quarter 2022 Financial Results and Recent Business Highlights

- Discussions underway between the University of Newcastle and GBS to oversee the high-tech manufacturing facility supported by its $4.7 Million Grant Funding Award from Australian Government - - $11.19 Million in Cash, Cash Equivalents, and Marketable Securities as of December 31, 2021, Provides Estimated Runway into H1 2023 - -To Host Conference Call and Webcast Today at 4:30 p.m. ET- NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-inv

Yahoo | February 10, 2022

GBS Inc. to Present Second Quarter 2022 Financial Results and Recent Corporate Update on February 10

Company to Host Conference Call & Webcast at 4:30 p.m. ETNEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point-of-care, today announced that it will release its financial results for the second quarter ended December 31, 2021, shortly after the NASDAQ market close on Thursday, February 10. Management will then host a conference call and webcast

Yahoo | February 7, 2022

Here's Why We're Watching GBS' (NASDAQ:GBS) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | January 23, 2022

GBS: Spit it Out: Testing Without the Blood

By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT The number of diagnostic tests used to evaluate biological material has exploded over the last decades. These tests help identify disease, determine treatment and show whether or not a condition is under control among other benefits. One of the earliest conditions evaluated using diagnostic tests was diabetes. The first

Yahoo | January 3, 2022

Read More 'GBS' Stories Here

GBS Price Returns

1-mo 15.34%
3-mo -45.45%
6-mo -56.58%
1-year -80.65%
3-year N/A
5-year N/A
YTD -54.01%
2021 -80.61%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6897 seconds.